AVEO Pharmaceuticals, Inc.
USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER

Abstract:

Disclosed is a method of treating cancer, e.g., refractory cancer, with tivozanib. The methods disclosed include, for example, administering tivozanib as a second or third-line therapy to subjects suffering from refractory advanced renal cell carcinoma where traditional therapies as well as more recent targeted and immune-oncology therapies have not adequately treated the subject.